<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Fri, 05 Jun 2026 06:02:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Form  6-K        IMMUTEP Ltd               For: Jun 04</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Jun+04/26607940.html</link>
   <description>si-local-file:///var/storage/secattach/20260605/26607940.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Jun+04/26607940.html</guid>
   <pubDate>Fri, 05 Jun 2026 06:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>Form  6-K        IMMUTEP Ltd               For: Jun 04</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Jun+04/26607940.html</link>
   <description>si-local-file:///var/storage/secattach/20260605/26607940.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Jun+04/26607940.html</guid>
   <pubDate>Fri, 05 Jun 2026 06:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>Form  6-K        IMMUTEP Ltd               For: Jun 04</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Jun+04/26607940.html</link>
   <description>si-local-file:///var/storage/secattach/20260605/26607940.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Jun+04/26607940.html</guid>
   <pubDate>Fri, 05 Jun 2026 06:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>SueWallSt Reminds Immutep Limited Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 6, 2026 - IMMP</title>
   <link>http://www.streetinsider.com/Press+Releases/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Notice to Pension Funds, Asset Managers, and Fiduciaries Holding IMMP: An 83% Single-Day Loss in Immutep ADRs Raises Urgent Questions About Portfolio Exposure and Fiduciary Recovery Obligations&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 28, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- Institutional investors holding positions in Immutep Limited (NASDAQ: IMMP) during the period from &lt;chron&gt;March 24, 2025&lt;/chron&gt; through &lt;chron&gt;March 12, 2026&lt;/chron&gt; may wish to evaluate lead plaintiff opportunities in a pending securities class action. &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4698020-6&amp;amp;h=4221010898&amp;amp;u=https%3A%2F%2Fsuewallst.com%2Fcases%2Fimmutep-limited-lawsuit-submission-form%3Fprid%3D186206%26wire%3D4&amp;amp;a=Request+an+institutional+investor+loss+assessment&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;Request an institutional investor loss assessment&lt;/a&gt;. You may also contact &lt;person&gt;Joseph E. Levi&lt;/person&gt;, Esq. at &lt;a target=&quot;_blank&quot; href=&quot;mailto:jlevi@SueWallSt.com&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;jlevi@SueWallSt.com&lt;/a&gt; or (888) SueWallSt.&lt;/p&gt;
   </description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html</guid>
   <pubDate>Thu, 28 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>SueWallSt Reminds Immutep Limited Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 6, 2026 - IMMP</title>
   <link>http://www.streetinsider.com/Press+Releases/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Notice to Pension Funds, Asset Managers, and Fiduciaries Holding IMMP: An 83% Single-Day Loss in Immutep ADRs Raises Urgent Questions About Portfolio Exposure and Fiduciary Recovery Obligations&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 28, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- Institutional investors holding positions in Immutep Limited (NASDAQ: IMMP) during the period from &lt;chron&gt;March 24, 2025&lt;/chron&gt; through &lt;chron&gt;March 12, 2026&lt;/chron&gt; may wish to evaluate lead plaintiff opportunities in a pending securities class action. &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4698020-6&amp;amp;h=4221010898&amp;amp;u=https%3A%2F%2Fsuewallst.com%2Fcases%2Fimmutep-limited-lawsuit-submission-form%3Fprid%3D186206%26wire%3D4&amp;amp;a=Request+an+institutional+investor+loss+assessment&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;Request an institutional investor loss assessment&lt;/a&gt;. You may also contact &lt;person&gt;Joseph E. Levi&lt;/person&gt;, Esq. at &lt;a target=&quot;_blank&quot; href=&quot;mailto:jlevi@SueWallSt.com&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;jlevi@SueWallSt.com&lt;/a&gt; or (888) SueWallSt.&lt;/p&gt;
   </description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html</guid>
   <pubDate>Thu, 28 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>SueWallSt Reminds Immutep Limited Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 6, 2026 - IMMP</title>
   <link>http://www.streetinsider.com/Press+Releases/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Notice to Pension Funds, Asset Managers, and Fiduciaries Holding IMMP: An 83% Single-Day Loss in Immutep ADRs Raises Urgent Questions About Portfolio Exposure and Fiduciary Recovery Obligations&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 28, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- Institutional investors holding positions in Immutep Limited (NASDAQ: IMMP) during the period from &lt;chron&gt;March 24, 2025&lt;/chron&gt; through &lt;chron&gt;March 12, 2026&lt;/chron&gt; may wish to evaluate lead plaintiff opportunities in a pending securities class action. &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4698020-6&amp;amp;h=4221010898&amp;amp;u=https%3A%2F%2Fsuewallst.com%2Fcases%2Fimmutep-limited-lawsuit-submission-form%3Fprid%3D186206%26wire%3D4&amp;amp;a=Request+an+institutional+investor+loss+assessment&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;Request an institutional investor loss assessment&lt;/a&gt;. You may also contact &lt;person&gt;Joseph E. Levi&lt;/person&gt;, Esq. at &lt;a target=&quot;_blank&quot; href=&quot;mailto:jlevi@SueWallSt.com&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;jlevi@SueWallSt.com&lt;/a&gt; or (888) SueWallSt.&lt;/p&gt;
   </description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html</guid>
   <pubDate>Thu, 28 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>SueWallSt Reminds Immutep Limited Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 6, 2026 - IMMP</title>
   <link>http://www.streetinsider.com/PRNewswire/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Notice to Pension Funds, Asset Managers, and Fiduciaries Holding IMMP: An 83% Single-Day Loss in Immutep ADRs Raises Urgent Questions About Portfolio Exposure and Fiduciary Recovery Obligations&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 28, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- Institutional investors holding positions in Immutep Limited (NASDAQ: IMMP) during the period from &lt;chron&gt;March 24, 2025&lt;/chron&gt; through &lt;chron&gt;March 12, 2026&lt;/chron&gt; may wish to evaluate lead plaintiff opportunities in a pending securities class action. &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4698020-6&amp;amp;h=4221010898&amp;amp;u=https%3A%2F%2Fsuewallst.com%2Fcases%2Fimmutep-limited-lawsuit-submission-form%3Fprid%3D186206%26wire%3D4&amp;amp;a=Request+an+institutional+investor+loss+assessment&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;Request an institutional investor loss assessment&lt;/a&gt;. You may also contact &lt;person&gt;Joseph E. Levi&lt;/person&gt;, Esq. at &lt;a target=&quot;_blank&quot; href=&quot;mailto:jlevi@SueWallSt.com&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;jlevi@SueWallSt.com&lt;/a&gt; or (888) SueWallSt.&lt;/p&gt;
   </description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html</guid>
   <pubDate>Thu, 28 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>SueWallSt Reminds Immutep Limited Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 6, 2026 - IMMP</title>
   <link>http://www.streetinsider.com/PRNewswire/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Notice to Pension Funds, Asset Managers, and Fiduciaries Holding IMMP: An 83% Single-Day Loss in Immutep ADRs Raises Urgent Questions About Portfolio Exposure and Fiduciary Recovery Obligations&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 28, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- Institutional investors holding positions in Immutep Limited (NASDAQ: IMMP) during the period from &lt;chron&gt;March 24, 2025&lt;/chron&gt; through &lt;chron&gt;March 12, 2026&lt;/chron&gt; may wish to evaluate lead plaintiff opportunities in a pending securities class action. &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4698020-6&amp;amp;h=4221010898&amp;amp;u=https%3A%2F%2Fsuewallst.com%2Fcases%2Fimmutep-limited-lawsuit-submission-form%3Fprid%3D186206%26wire%3D4&amp;amp;a=Request+an+institutional+investor+loss+assessment&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;Request an institutional investor loss assessment&lt;/a&gt;. You may also contact &lt;person&gt;Joseph E. Levi&lt;/person&gt;, Esq. at &lt;a target=&quot;_blank&quot; href=&quot;mailto:jlevi@SueWallSt.com&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;jlevi@SueWallSt.com&lt;/a&gt; or (888) SueWallSt.&lt;/p&gt;
   </description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html</guid>
   <pubDate>Thu, 28 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>SueWallSt Reminds Immutep Limited Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 6, 2026 - IMMP</title>
   <link>http://www.streetinsider.com/PRNewswire/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html</link>
   <description>
&lt;div class=&quot;xn-content&quot;&gt;
&lt;p&gt;&lt;i&gt;Notice to Pension Funds, Asset Managers, and Fiduciaries Holding IMMP: An 83% Single-Day Loss in Immutep ADRs Raises Urgent Questions About Portfolio Exposure and Fiduciary Recovery Obligations&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;legendSpanClass&quot;&gt;&lt;location value=&quot;LU/us.ny.nyc&quot; idsrc=&quot;xmltag.org&quot; &gt;NEW YORK&lt;/location&gt;&lt;/span&gt;, &lt;span class=&quot;legendSpanClass&quot;&gt;&lt;chron&gt;May 28, 2026&lt;/chron&gt;&lt;/span&gt; /PRNewswire/ -- Institutional investors holding positions in Immutep Limited (NASDAQ: IMMP) during the period from &lt;chron&gt;March 24, 2025&lt;/chron&gt; through &lt;chron&gt;March 12, 2026&lt;/chron&gt; may wish to evaluate lead plaintiff opportunities in a pending securities class action. &lt;a target=&quot;_blank&quot; href=&quot;https://edge.prnewswire.com/c/link/?t=0&amp;amp;l=en&amp;amp;o=4698020-6&amp;amp;h=4221010898&amp;amp;u=https%3A%2F%2Fsuewallst.com%2Fcases%2Fimmutep-limited-lawsuit-submission-form%3Fprid%3D186206%26wire%3D4&amp;amp;a=Request+an+institutional+investor+loss+assessment&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;Request an institutional investor loss assessment&lt;/a&gt;. You may also contact &lt;person&gt;Joseph E. Levi&lt;/person&gt;, Esq. at &lt;a target=&quot;_blank&quot; href=&quot;mailto:jlevi@SueWallSt.com&quot; target=&quot;_blank&quot; rel=&quot;nofollow&quot;&gt;jlevi@SueWallSt.com&lt;/a&gt; or (888) SueWallSt.&lt;/p&gt;
   </description>
   <guid isPermaLink="true">http://www.streetinsider.com/PRNewswire/SueWallSt+Reminds+Immutep+Limited+Investors+of+the+Pending+Class+Action+Lawsuit+With+a+Lead+Plaintiff+Deadline+of+July+6%2C+2026+-+IMMP/26562231.html</guid>
   <pubDate>Thu, 28 May 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>Form  6-K        IMMUTEP Ltd               For: Apr 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Apr+30/26417347.html</link>
   <description>si-local-file:///var/storage/secattach/20260501/26417347.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Apr+30/26417347.html</guid>
   <pubDate>Fri, 01 May 2026 15:57:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PRRUF</category>
   	  </item>
  <item>
   <title>Form  6-K        IMMUTEP Ltd               For: Apr 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Apr+30/26417347.html</link>
   <description>si-local-file:///var/storage/secattach/20260501/26417347.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Apr+30/26417347.html</guid>
   <pubDate>Fri, 01 May 2026 15:57:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PRRUF</category>
   	  </item>
  <item>
   <title>Form  6-K        IMMUTEP Ltd               For: Apr 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Apr+30/26417347.html</link>
   <description>si-local-file:///var/storage/secattach/20260501/26417347.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Apr+30/26417347.html</guid>
   <pubDate>Fri, 01 May 2026 15:57:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PRRUF</category>
   	  </item>
  <item>
   <title>Form  6-K        IMMUTEP Ltd               For: Apr 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Apr+30/26414086.html</link>
   <description>si-local-file:///var/storage/secattach/20260501/26414086.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Apr+30/26414086.html</guid>
   <pubDate>Fri, 01 May 2026 09:55:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PRRUF</category>
   	  </item>
  <item>
   <title>Form  6-K        IMMUTEP Ltd               For: Apr 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Apr+30/26414086.html</link>
   <description>si-local-file:///var/storage/secattach/20260501/26414086.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Apr+30/26414086.html</guid>
   <pubDate>Fri, 01 May 2026 09:55:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PRRUF</category>
   	  </item>
  <item>
   <title>Form  6-K        IMMUTEP Ltd               For: Apr 30</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Apr+30/26414086.html</link>
   <description>si-local-file:///var/storage/secattach/20260501/26414086.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++IMMUTEP+Ltd+++++++++++++++For%3A+Apr+30/26414086.html</guid>
   <pubDate>Fri, 01 May 2026 09:55:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">PRRUF</category>
   	  </item>
  <item>
   <title>Immutep Quarterly Activities Report Q3 FY26</title>
   <link>http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</link>
   <description>
&lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.&lt;/li&gt;&lt;/ul&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;b&gt;&lt;b&gt;SYDNEY, AUSTRALIA, April  30, 2026  (GLOBE NEWSWIRE) -- &lt;/b&gt;&lt;/b&gt;&lt;a target=&quot;_blank&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</guid>
   <pubDate>Thu, 30 Apr 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.37819586</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00000304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>Immutep Quarterly Activities Report Q3 FY26</title>
   <link>http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</link>
   <description>
&lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.&lt;/li&gt;&lt;/ul&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;b&gt;&lt;b&gt;SYDNEY, AUSTRALIA, April  30, 2026  (GLOBE NEWSWIRE) -- &lt;/b&gt;&lt;/b&gt;&lt;a target=&quot;_blank&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</guid>
   <pubDate>Thu, 30 Apr 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.37819586</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00000304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>Immutep Quarterly Activities Report Q3 FY26</title>
   <link>http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</link>
   <description>
&lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.&lt;/li&gt;&lt;/ul&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;b&gt;&lt;b&gt;SYDNEY, AUSTRALIA, April  30, 2026  (GLOBE NEWSWIRE) -- &lt;/b&gt;&lt;/b&gt;&lt;a target=&quot;_blank&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</guid>
   <pubDate>Thu, 30 Apr 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.37819586</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00000304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>Immutep Quarterly Activities Report Q3 FY26</title>
   <link>http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</link>
   <description>
&lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.&lt;/li&gt;&lt;/ul&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;b&gt;&lt;b&gt;SYDNEY, AUSTRALIA, April  30, 2026  (GLOBE NEWSWIRE) -- &lt;/b&gt;&lt;/b&gt;&lt;a target=&quot;_blank&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</guid>
   <pubDate>Thu, 30 Apr 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.37819586</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00000304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>Immutep Quarterly Activities Report Q3 FY26</title>
   <link>http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</link>
   <description>
&lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.&lt;/li&gt;&lt;/ul&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;b&gt;&lt;b&gt;SYDNEY, AUSTRALIA, April  30, 2026  (GLOBE NEWSWIRE) -- &lt;/b&gt;&lt;/b&gt;&lt;a target=&quot;_blank&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</guid>
   <pubDate>Thu, 30 Apr 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.37819586</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00000304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>Immutep Quarterly Activities Report Q3 FY26</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</link>
   <description>
&lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.&lt;/li&gt;&lt;/ul&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;b&gt;&lt;b&gt;SYDNEY, AUSTRALIA, April  30, 2026  (GLOBE NEWSWIRE) -- &lt;/b&gt;&lt;/b&gt;&lt;a target=&quot;_blank&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</guid>
   <pubDate>Thu, 30 Apr 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.37819586</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00000304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>Immutep Quarterly Activities Report Q3 FY26</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</link>
   <description>
&lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.&lt;/li&gt;&lt;/ul&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;b&gt;&lt;b&gt;SYDNEY, AUSTRALIA, April  30, 2026  (GLOBE NEWSWIRE) -- &lt;/b&gt;&lt;/b&gt;&lt;a target=&quot;_blank&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</guid>
   <pubDate>Thu, 30 Apr 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.37819586</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00000304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>Immutep Quarterly Activities Report Q3 FY26</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</link>
   <description>
&lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.&lt;/li&gt;&lt;/ul&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;b&gt;&lt;b&gt;SYDNEY, AUSTRALIA, April  30, 2026  (GLOBE NEWSWIRE) -- &lt;/b&gt;&lt;/b&gt;&lt;a target=&quot;_blank&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</guid>
   <pubDate>Thu, 30 Apr 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.37819586</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00000304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>Immutep Quarterly Activities Report Q3 FY26</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</link>
   <description>
&lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.&lt;/li&gt;&lt;/ul&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;b&gt;&lt;b&gt;SYDNEY, AUSTRALIA, April  30, 2026  (GLOBE NEWSWIRE) -- &lt;/b&gt;&lt;/b&gt;&lt;a target=&quot;_blank&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</guid>
   <pubDate>Thu, 30 Apr 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.37819586</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00000304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
  <item>
   <title>Immutep Quarterly Activities Report Q3 FY26</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</link>
   <description>
&lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Root cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under review&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Phase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026&lt;/li&gt;&lt;li style=&quot;margin-top:8pt; margin-bottom:8pt;&quot;&gt;Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash reach into H1 CY2028 based on current assumptions.&lt;/li&gt;&lt;/ul&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;b&gt;&lt;b&gt;SYDNEY, AUSTRALIA, April  30, 2026  (GLOBE NEWSWIRE) -- &lt;/b&gt;&lt;/b&gt;&lt;a target=&quot;_blank&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Immutep+Quarterly+Activities+Report+Q3+FY26/26400880.html</guid>
   <pubDate>Thu, 30 Apr 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.37819586</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMM</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">IMMP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00000304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00768283</category>
   	  </item>
 </channel>
</rss>
